• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早产儿视网膜病变激光光凝术后 1 年矫正年龄近视的危险因素。

Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity.

机构信息

Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Eye (Lond). 2021 Oct;35(10):2820-2825. doi: 10.1038/s41433-020-01321-z. Epub 2020 Nov 30.

DOI:10.1038/s41433-020-01321-z
PMID:33257802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8452716/
Abstract

BACKGROUND/OBJECTIVES: The prevalence of myopia is higher in preterm infants who underwent laser photocoagulation (LPC) for retinopathy of prematurity (ROP). The aim of this study was to investigate factors associated with myopia in preterm infants who undergo LPC for ROP.

SUBJECTS/METHODS: We retrospectively analysed the medical records of preterm infants born at Kyushu University Hospital (October 2008-March 2018) at ≤32 weeks of gestational age or with birth weight ≤1500 g. We evaluated the associations between nine clinical factors and the spherical equivalent at 1-year corrected age by performing multivariable linear regression in LPC-treated ROP patients.

RESULTS

Among the 485 infants enroled, 76 developed ROP requiring treatment. Of these, 71 underwent LPC, which was provided to 63 infants as the primary treatment (LPC alone or the combination therapy of LPC and intravitreal injection of bevacizumab [IVB]) and to eight infants as additional LPC after IVB monotherapy. The results of a refractive examination at 1-year corrected age were available for 110 eyes of 56 infants (78.9%). The mean ± standard deviation of the SE value was -0.5 ± 3.0 dioptres (D). Multivariable linear regression analysis revealed a significant association between laser spot count and SE value (ß = -0.081 ± 0.040 D per 100 spots [mean ± standard error], p = 0.045).

CONCLUSIONS

Our results suggest that an increased laser spot count observed during ROP treatment associates with myopia.

摘要

背景/目的:早产儿接受激光光凝(LPC)治疗早产儿视网膜病变(ROP)后,近视的患病率更高。本研究旨在探讨接受 LPC 治疗 ROP 的早产儿近视的相关因素。

方法

我们回顾性分析了九州大学医院(2008 年 10 月至 2018 年 3 月)出生胎龄≤32 周或出生体重≤1500g 的早产儿的病历。我们通过多变量线性回归分析 LPC 治疗 ROP 患者的 9 个临床因素与 1 年矫正年龄时的球镜等效值之间的关系。

结果

在纳入的 485 名婴儿中,有 76 名患有需要治疗的 ROP。其中,71 名婴儿接受了 LPC,63 名婴儿接受了 LPC 作为主要治疗(LPC 单独或 LPC 联合玻璃体腔内注射贝伐单抗[IVB]),8 名婴儿接受了 IVB 单药治疗后额外的 LPC。56 名婴儿(78.9%)的 110 只眼可获得 1 年矫正年龄时的屈光检查结果。SE 值的平均值±标准差为-0.5±3.0 屈光度(D)。多变量线性回归分析显示,激光光斑数与 SE 值之间存在显著关联(每 100 个光斑 SE 值的变化量为-0.081±0.040 D[平均值±标准误],p=0.045)。

结论

我们的结果表明,ROP 治疗过程中观察到的激光光斑数增加与近视有关。

相似文献

1
Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity.早产儿视网膜病变激光光凝术后 1 年矫正年龄近视的危险因素。
Eye (Lond). 2021 Oct;35(10):2820-2825. doi: 10.1038/s41433-020-01321-z. Epub 2020 Nov 30.
2
One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.玻璃体腔内注射贝伐单抗与激光光凝治疗早产儿视网膜病变的 1 年屈光结果。
Int Ophthalmol. 2023 Jul;43(7):2197-2202. doi: 10.1007/s10792-022-02615-9. Epub 2022 Dec 15.
3
Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?激光治疗早产儿视网膜病变后近视的发展:早产还是激光光凝?
Int Ophthalmol. 2023 May;43(5):1453-1458. doi: 10.1007/s10792-022-02540-x. Epub 2022 Sep 23.
4
Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.贝伐单抗、雷珠单抗和激光光凝治疗土耳其早产儿视网膜病变的比较。
Curr Eye Res. 2017 Mar;42(3):462-469. doi: 10.1080/02713683.2016.1196709. Epub 2016 Jul 15.
5
Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.前瞻性临床研究两种不同治疗方案联合激光光凝和玻璃体内贝伐单抗治疗早产儿视网膜病变:印度双子城 ROP 研究(ITCROPS)数据库报告第 9 号。
Int Ophthalmol. 2020 Dec;40(12):3539-3545. doi: 10.1007/s10792-020-01543-w. Epub 2020 Aug 10.
6
Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.玻璃体腔注射贝伐单抗与激光光凝治疗早产儿视网膜病变的5年回顾性分析结果
Ophthalmology. 2015 May;122(5):1008-15. doi: 10.1016/j.ophtha.2014.12.017. Epub 2015 Feb 14.
7
Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity.玻璃体内注射贝伐单抗治疗 1 型早产儿视网膜病变的日本早产儿的神经发育结局。
PLoS One. 2020 Mar 20;15(3):e0230678. doi: 10.1371/journal.pone.0230678. eCollection 2020.
8
Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.早产儿视网膜病变激光光凝与玻璃体腔内注射bevacizumab 治疗 5 年的安全性和疗效比较。
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2849-2855. doi: 10.1007/s00417-021-05137-9. Epub 2021 Mar 21.
9
Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.与传统激光治疗相比,贝伐单抗单药治疗后的屈光结果:一项随机临床试验。
JAMA Ophthalmol. 2014 Nov;132(11):1327-33. doi: 10.1001/jamaophthalmol.2014.2772.
10
Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.玻璃体内注射贝伐单抗或激光光凝治疗早产儿视网膜病变的屈光度纵向变化。
Am J Ophthalmol. 2022 Aug;240:252-259. doi: 10.1016/j.ajo.2022.03.020. Epub 2022 Mar 31.

引用本文的文献

1
Therapeutic outcomes of ranibizumab for zone ii stage 2 retinopathy of prematurity with plus disease.雷珠单抗治疗Ⅱ区2期伴有Plus病变的早产儿视网膜病变的疗效。
Jpn J Ophthalmol. 2025 May 16. doi: 10.1007/s10384-025-01199-y.
2
Association between myopia progression and quantity of laser treatment for retinopathy of prematurity.近视进展与早产儿视网膜病变激光治疗量的关系。
PLoS One. 2022 Dec 30;17(12):e0279898. doi: 10.1371/journal.pone.0279898. eCollection 2022.
3
One year follow-up of intravitreal bevacizumab injection in Aggressive Retinopathy of Prematurity at Indonesian national referral hospital: Case series.印度尼西亚国家转诊医院玻璃体内注射贝伐单抗治疗早产儿侵袭性视网膜病变的一年随访:病例系列
Ann Med Surg (Lond). 2022 Nov 11;84:104853. doi: 10.1016/j.amsu.2022.104853. eCollection 2022 Dec.
4
Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab.玻璃体内注射贝伐单抗治疗后眼的屈光度结果与定量视网膜血管化及 + 病严重程度的关系。
Indian J Ophthalmol. 2022 Oct;70(10):3584-3590. doi: 10.4103/ijo.IJO_243_22.
5
Development of myopia in laser-treated ROP infants: prematurity or laser photocoagulation?激光治疗早产儿视网膜病变后近视的发展:早产还是激光光凝?
Int Ophthalmol. 2023 May;43(5):1453-1458. doi: 10.1007/s10792-022-02540-x. Epub 2022 Sep 23.
6
Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity.玻璃体内注射雷珠单抗治疗三种类型早产儿视网膜病变的疗效评估
Int J Ophthalmol. 2022 May 18;15(5):753-759. doi: 10.18240/ijo.2022.05.10. eCollection 2022.
7
Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.玻璃体内注射贝伐单抗或激光光凝治疗早产儿视网膜病变的屈光度纵向变化。
Am J Ophthalmol. 2022 Aug;240:252-259. doi: 10.1016/j.ajo.2022.03.020. Epub 2022 Mar 31.

本文引用的文献

1
Outcome of solid-state 532 nm green laser in high-risk retinopathy of prematurity at a tertiary care centre in India.印度一家三级医疗中心采用固态532纳米绿色激光治疗高危早产儿视网膜病变的结果
Int Ophthalmol. 2018 Feb;38(1):287-291. doi: 10.1007/s10792-017-0460-3. Epub 2017 Feb 15.
2
Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.早产儿视网膜病变早期治疗(ETROP)随机试验的最终结果。
Trans Am Ophthalmol Soc. 2004;102:233-48; discussion 248-50.